17 December 2025   Hesperos announces the establishment of a strategic channel sales and marketing partnership with AsedaSciences, offering its pharmaceutical, cosmetic, nutraceutical and chemical industry clients a powerful combination of human-based, in silico and in vitro tools for development of safer compounds.   Traditionally, compound safety has been assessed using animal testing, but these models raise ethical concerns, lack human physiological relevance, and offer l

23 September 2025   Vienna-based Heartbeat.bio , developer of breakthrough therapies for cardiac disorders through its proprietary human-based in vitro cardioid drug discovery platform, announces  it has entered into a research collaboration with Boehringer Ingelheim to develop gene therapy-based treatments for genetic cardiomyopathies.   Genetic cardiac pathologies such as hypertrophic, dilated, arrhythmogenic right ventricular and restrictive cardiomyopathy, are typically c

09 December 2025   Riccardo Levato’s team at UMC Utrecht and Utrecht University receives  an ERC Consolidator Grant of approx. €2.3M to advance the next phase of its innovative method of 3D bioprinting.     The technique of 3D bioprinting of living tissues to recapitulate the structure and function of human organs has shown great promise in disease modelling, drug testing and regenerative medicine. Supported by a 2020 ERC Starting Grant, Riccardo Levato’s team developed a mod

17 October 2025   Hesperos Inc. has been awarded  a Phase IIB SBIR grant from the National Institute on Aging to investigate the effects of medication on cognitive impairment.   In humans, drug-induced cognitive decline may arise from subtle network‑level disruption, synaptic dysfunction, neurotransmitter imbalance and moderate neuroinflammation. However, these effects are very challenging to detect using standard in vitro models and animal testing. Cognitive decline is typic

16 September 2025   Franco-American CRO Genoskin  announces it has raised  $8.7M in its first funding round led by OCCTE (FPCI Occidev Impacts) to grow its human ex vivo skin platform.   In a field that struggles to bridge the gap between preclinical promise and clinical outcome, the project carried by Genoskin has a particular significance. The development of vaccines and therapies for human skin diseases is fraught with difficulties, not least of which is the existence of n

25 September 2025   Cedars-Sinai Medical Center based in Los Angeles has been awarded $5M by Advanced Research Projects Agency for Health (ARPA-H) to develop a human-based AI-driven KronosRx platform  for improved prediction of adverse drug effects.   The ARPA-H Computational ADME-Tox and Physiology Analysis for Safer Therapeutics ( CATALYST ) program aims to revolutionize preclinical drug safety prediction by facilitating the development of next gen in vitro and in silico mo

12 June 2025   Cambridge, Massachusetts-based Parallel Bio announces  it has raised $21 million Series A funding to scale up and automate the production of its immune organoid in vitro platform. This funding round led by AIX Ventures was supported by prominent leaders in AI and biotech, including Marc Benioff, founder and CEO of Salesforce.   Beyond infections and autoimmune diseases, it is widely recognized that the human immune systems plays a key role in a great number of

30 June 2025   The Ministry of Health, Labour and Welfare in Japan has granted orphan drug designation to riliprubart for treating chronic inflammatory demyelinating polyneuropathy (CIDP), Sanofi reports . Riliprubart also holds this designation for CIDP in the EU and US.   By engineering its human-relevant CIDP-on-chip as preclinical tool for disease modelling and drug efficacy testing, Hesperos has played an instrumental role in achieving this outcome.   CIDP is an inflamma